Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Principles of adoptive T cell therapy in cancer.

Literature DB >> 30187086

Principles of adoptive T cell therapy in cancer.

Özcan Met^1,2,3, Kasper Mølgaard Jensen⁴, Christopher Aled Chamberlain⁴, Marco Donia^4,5, Inge Marie Svane^4,5.

Abstract

Adoptive cell therapy (ACT) utilizing either tumor-infiltrating lymphocyte (TIL)-derived T cells or T cells genetically engineered to express tumor recognizing receptors has emerged as a powerful and potentially curative therapy for several cancers. Many ACT-based therapies have recently entered late-phase clinical testing, with several T cell therapies already achieving regulatory approval for the treatment of patients with B cell malignancies. In this review, we briefly outline the principles of adoptively transferred T cells for the treatment of cancer.

Entities: Disease Species

Keywords: Adoptive cell therapy; Cancer immunotherapy; Chimeric antigen receptor; T cells; Tumor-infiltrating lymphocytes

Mesh：

Substances：

Year: 2018 PMID： 30187086 DOI： 10.1007/s00281-018-0703-z

Source DB: PubMed Journal: Semin Immunopathol ISSN： 1863-2297 Impact factor: 9.623

73 in total

1. Nivolumab in previously untreated melanoma without BRAF mutation.

Authors: Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal: N Engl J Med Date: 2014-11-16 Impact factor: 91.245

2. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution.

Authors: M Donia; N Junker; E Ellebaek; M H Andersen; P T Straten; I M Svane
Journal: Scand J Immunol Date: 2012-02 Impact factor: 3.487

3. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience.

Authors: J R Yannelli; C Hyatt; S McConnell; K Hines; L Jacknin; L Parker; M Sanders; S A Rosenberg
Journal: Int J Cancer Date: 1996-02-08 Impact factor: 7.396

4. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors: Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal: J Clin Oncol Date: 2005-04-01 Impact factor: 44.544

5. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors: S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal: N Engl J Med Date: 1988-12-22 Impact factor: 91.245

6. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors: Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal: Sci Transl Med Date: 2014-02-19 Impact factor: 17.956

7. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors: Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal: Science Date: 2002-09-19 Impact factor: 47.728

8. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.

Authors: Paul F Robbins; Yong F Li; Mona El-Gamil; Yangbing Zhao; Jennifer A Wargo; Zhili Zheng; Hui Xu; Richard A Morgan; Steven A Feldman; Laura A Johnson; Alan D Bennett; Steven M Dunn; Tara M Mahon; Bent K Jakobsen; Steven A Rosenberg
Journal: J Immunol Date: 2008-05-01 Impact factor: 5.422

9. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors: Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal: N Engl J Med Date: 2018-02-01 Impact factor: 91.245

10. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.

Authors: Michal J Besser; Ronnie Shapira-Frommer; Orit Itzhaki; Avraham J Treves; Douglas B Zippel; Daphna Levy; Adva Kubi; Noa Shoshani; Dragoslav Zikich; Yaara Ohayon; Daniel Ohayon; Bruria Shalmon; Gal Markel; Ronit Yerushalmi; Sara Apter; Alon Ben-Nun; Eytan Ben-Ami; Avichai Shimoni; Arnon Nagler; Jacob Schachter
Journal: Clin Cancer Res Date: 2013-05-20 Impact factor: 12.531

42 in total

1. Anti-cancer immunotherapy: breakthroughs and future strategies.

Authors: Mads Hald Andersen
Journal: Semin Immunopathol Date: 2018-09-21 Impact factor: 9.623

Review 2. Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.

Authors: Gerald P Linette; Beatriz M Carreno
Journal: Curr Hematol Malig Rep Date: 2019-08 Impact factor: 3.952

3. Magnetic Particle Imaging Is a Sensitive In Vivo Imaging Modality for the Detection of Dendritic Cell Migration.

Authors: Julia J Gevaert; Corby Fink; Jimmy D Dikeakos; Gregory A Dekaban; Paula J Foster
Journal: Mol Imaging Biol Date: 2022-06-01 Impact factor: 3.488

Review 4. A Darwinian perspective on tumor immune evasion.

Authors: Julieann Puleo; Kornelia Polyak
Journal: Biochim Biophys Acta Rev Cancer Date: 2021-12-18 Impact factor: 10.680

Review 5. Recent Progress in the Synergistic Combination of Nanoparticle-Mediated Hyperthermia and Immunotherapy for Treatment of Cancer.

Authors: Zachary R Stephen; Miqin Zhang
Journal: Adv Healthc Mater Date: 2020-11-25 Impact factor: 9.933

Review 6. CRISPR/Cas9 for the Clinician: Current uses of gene editing and applications for new therapeutics in oncology.

Authors: Julia Boland; Elena Nedelcu
Journal: Perm J Date: 2020-12

Review 7. Promises and challenges of adoptive T-cell therapies for solid tumours.

Authors: Matteo Morotti; Ashwag Albukhari; Abdulkhaliq Alsaadi; Mara Artibani; James D Brenton; Stuart M Curbishley; Tao Dong; Michael L Dustin; Zhiyuan Hu; Nicholas McGranahan; Martin L Miller; Laura Santana-Gonzalez; Leonard W Seymour; Tingyan Shi; Peter Van Loo; Christopher Yau; Helen White; Nina Wietek; David N Church; David C Wedge; Ahmed A Ahmed
Journal: Br J Cancer Date: 2021-03-29 Impact factor: 7.640